This phase of the research was bolstered by the expertise of James Smyth, an associate professor at the Fralin Biomedical Research Institute. Smyth, who typically uses super-resolution microscopy to study the heart and how connexin proteins affect cardiac function during disease, collaborated with Lamouille to apply these high-tech imaging tools to brain cancer. Together, they made a landmark discovery: in glioblastoma stem cells, connexin 43 was not just forming bridges between cells. Instead, it was found to be heavily associated with microtubules—the long, thin filaments that make up the cell’s internal skeleton and serve as tracks for transporting materials.
The discovery that connexin 43 "decorated" the entire length of these microtubules suggested a specialized role for the protein in maintaining the stem-like properties of the cancer cells. This insight provided the spark for a new therapeutic strategy. Lamouille hypothesized that if they could disrupt the interaction between connexin 43 and the microtubules, they might be able to destabilize the stem cells.
To test this theory, Lamouille turned to a molecule called JM2. This peptide is a laboratory-designed fragment of the connexin 43 protein itself. Specifically, JM2 is engineered to mimic the exact part of connexin 43 that binds to microtubules. By introducing this "decoy" peptide into the cancer cells, the researchers hoped to prevent the actual connexin 43 protein from latching onto the microtubules, thereby breaking the internal machinery the cells rely on for survival.
The JM2 peptide was originally developed by Rob Gourdie, the Heywood Fralin professor at the Fralin Biomedical Research Institute. Gourdie, who created the peptide during his previous tenure at the Medical University of South Carolina, has long explored the therapeutic potential of targeting connexin proteins. When Lamouille applied Gourdie’s creation to the glioblastoma stem-like cells, the results were immediate and striking.
Lamouille describes the moment of discovery as the most exciting point in the study. The JM2 peptide did more than just disrupt the protein-microtubule interaction; it proved to be toxic to the glioblastoma stem cells. Crucially, the peptide appeared to be highly selective. While it effectively killed the treatment-resistant cancer cells, it left healthy, non-cancerous brain cells unharmed. Furthermore, the peptide achieved this "killing effect" without interfering with the other vital functions that connexin 43 performs in the body, such as maintaining normal cell-to-cell communication in healthy tissues.
The efficacy of the treatment was visually evident in the lab. Using three-dimensional models known as gliospheres—clusters of cells that mimic the structure of a real tumor—the researchers observed a significant physical change. Gourdie recalls seeing the gliospheres, which usually grow aggressively, clearly shrinking in size after being treated with the peptide. He noted that the fact that JM2 possessed such a potent killing effect on its own was unexpected and highly promising for future drug development.
The study moved from the petri dish to animal models, where the researchers sought to determine if the peptide could perform in a living organism. The results mirrored the laboratory findings: JM2 disrupted the maintenance of treatment-resistant cancer cells and significantly slowed the growth of tumors in vivo. These findings solidify the potential of JM2 as a new class of peptide-based drug, specifically designed to hit the "Achilles’ heel" of glioblastoma.
